Rationale and design of A Trial of Sertraline vs. Cognitive Behavioral Therapy for End-stage Renal Disease Patients with Depression (ASCEND)

Contemporary Clinical Trials

Volumn 47, Issue , 2016, Pages 1-11

  Hedayati, S Susan ^a,b   Daniel, Divya M ^c   Cohen, Scott ^d   Comstock, Bryan ^c   Cukor, Daniel ^e   Diaz Linhart, Yaminette ^f   Dember, Laura M ^g   Dubovsky, Amelia ^c   Greene, Tom ^h   Grote, Nancy ^c   Heagerty, Patrick ^c   Katon, Wayne ^c   Kimmel, Paul L ⁱ   Kutner, Nancy ^j   Linke, Lori ^c   Quinn, Davin ^k   Rue, Tessa ^c   Trivedi, Madhukar H ^l   Unruh, Mark ^m   Weisbord, Steven ⁿ   Young, Bessie A ^c   Mehrotra, Rajnish ^c   more..

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

^j EMORY UNIVERSITY   (United States)

^k UNIVERSITY OF NEW MEXICO   (United States)

^l UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^m UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Cognitive behavioral therapy (CBT); Depression; End Stage Renal Disease (ESRD); Engagement interview; Hemodialysis; Sertraline

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PLACEBO; PROTRIPTYLINE; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE; VILAZODONE; VORTIOXETINE; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; COGNITIVE THERAPY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSTHYMIA; END STAGE RENAL DISEASE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MENTAL PATIENT; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; NAUSEA AND VOMITING; OPEN STUDY; PROBABILITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DYSTHYMIC DISORDER; KIDNEY FAILURE, CHRONIC; MULTICENTER STUDY; PROCEDURES; PSYCHOLOGY;

ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DYSTHYMIC DISORDER; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; SERTRALINE; TREATMENT OUTCOME;

EID: 84959339587     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2015.11.020     Document Type: Article

References (87)

1. U.S.Renal Data System: USRDS Annual Report: Atlas of End-stage Renal Disease in the United States 2012, 2012:2012. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
2. Weisbord S.D., et al. Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J. Am. Soc. Nephrol. 2005, 16(8):2487-2494.
3. Fukuhara S., et al. Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2003, 64(5):1903-1910.
4. Mapes D.L., et al. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int. 2003, 64(1):339-349.
5. Chiu Y.W., et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin. J. Am. Soc. Nephrol. 2009, 4(6):1089-1096.
6. Kalantar-Zadeh K., et al. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J. Am. Soc. Nephrol. 2001, 12(12):2797-2806.
7. Kang E.W., et al. The association of mental health over time with cardiac outcomes in HEMO study patients. Clin. J. Am. Soc. Nephrol. 2012, 7(6):957-964.
8. Manley H.J., et al. Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol. Dial. Transplant. 2004, 19(7):1842-1848.
9. Palmer S., et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013, 84(1):179-191.
10. Drayer R.A., et al. Characteristics of depression in hemodialysis patients: symptoms, quality of life and mortality risk. Gen. Hosp. Psychiatry 2006, 28(4):306-312.
11. Hedayati S.S., et al. The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int. 2006, 69(9):1662-1668.
12. Peng Y.S., et al. Sexual dysfunction in female hemodialysis patients: a multicenter study. Kidney Int. 2005, 68(2):760-765.
13. Takaki J., Yano E. The relationship between coping with stress and employment in patients receiving maintenance hemodialysis. J. Occup. Health 2006, 48(4):276-283.
14. Kimmel P.L., et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int. 2000, 57(5):2093-2098.
15. Chilcot J., et al. An association between depressive symptoms and survival in incident dialysis patients. Nephrol. Dial. Transplant. 2011, 26(5):1628-1634.
16. Rosenthal Asher D., Ver Halen N., Cukor D. Depression and nonadherence predict mortality in hemodialysis treated end-stage renal disease patients. Hemodial. Int. 2012, 16(3):387-393.
17. Lopes A.A., et al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int. 2002, 62(1):199-207.
18. Edmondson D., et al. Association of posttraumatic stress disorder and depression with all-cause and cardiovascular disease mortality and hospitalization among Hurricane Katrina survivors with end-stage renal disease. Am. J. Public Health 2013, 103(4):e130-e137.
19. Riezebos R.K., et al. The association of depressive symptoms with survival in a Dutch cohort of patients with end-stage renal disease. Nephrol. Dial. Transplant. 2010, 25(1):231-236.
20. Boulware L.E., et al. Temporal relation among depression symptoms, cardiovascular disease events, and mortality in end-stage renal disease: contribution of reverse causality. Clin. J. Am. Soc. Nephrol. 2006, 1(3):496-504.
21. Hedayati S.S., et al. Death or hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of depression. Kidney Int. 2008, 74(7):930-936.
22. Lacson E., et al. Depressive symptoms associate with high mortality risk and dialysis withdrawal in incident hemodialysis patients. Nephrol. Dial. Transplant. 2012, 27(7):2921-2928.
23. Hedayati S.S., et al. Physician-diagnosed depression as a correlate of hospitalizations in patients receiving long-term hemodialysis. Am. J. Kidney Dis. 2005, 46(4):642-649.
24. Young B.A., et al. Association of major depression and mortality in tage 5 diabetic chronic kidney disease. Gen. Hosp. Psychiatry 2010, 32(2):119-124.
25. Halen N.V., et al. Depression and mortality in end-stage renal disease. Curr. Psychiatry Rep. 2012, 14(1):36-44.
26. Cohen S.D., et al. Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. Clin. J. Am. Soc. Nephrol. 2007, 2(6):1332-1342.
27. Kimmel P.L., et al. Depression in end-stage renal disease patients: a critical review. Adv. Chronic Kidney Dis. 2007, 14(4):328-334.
28. Palmer S.C., et al. Association between depression and death in people with CKD: a meta-analysis of cohort studies. Am. J. Kidney Dis. 2013, 62(3):493-505.
29. DiMatteo M.R., Lepper H.S., Croghan T.W. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 2000, 160(14):2101-2107.
30. Cukor D., et al. Depression is an important contributor to low medication adherence in hemodialyzed patients and transplant recipients. Kidney Int. 2009, 75(11):1223-1229.
31. Everett K.D., et al. The relation of stress and depression to interdialytic weight gain in hemodialysis patients. Behav. Med. 1995, 21(1):25-30.
32. Kimmel P.L., et al. Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients. Kidney Int. 1998, 54(1):245-254.
33. Kimmel P.L., et al. Behavioral compliance with dialysis prescription in hemodialysis patients. J. Am. Soc. Nephrol. 1995, 5(10):1826-1834.
34. Kutner N.G., et al. Psychosocial predictors of non-compliance in haemodialysis and peritoneal dialysis patients. Nephrol. Dial. Transplant. 2002, 17(1):93-99.
35. Saran R., et al. Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int. 2003, 64(1):254-262.
36. Untas A., et al. The associations of social support and other psychosocial factors with mortality and quality of life in the dialysis outcomes and practice patterns study. Clin. J. Am. Soc. Nephrol. 2011, 6(1):142-152.
37. Nagler E.V., et al. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol. Dial. Transplant. 2012, 27(10):3736-3745.
38. Glassman A.H., et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002, 288(6):701-709.
39. Kimmel P.L., Peterson R.A. Depression in patients with end-stage renal disease treated with dialysis: has the time to treat arrived?. Clin. J. Am. Soc. Nephrol. 2006, 1(3):349-352.
40. Weisbord S.D., et al. Comparison of symptom management strategies for pain, erectile dysfunction, and depression in patients receiving chronic hemodialysis: a cluster randomized effectiveness trial. Clin. J. Am. Soc. Nephrol. 2013, 8(1):90-99.
41. Blumenfield M., et al. Fluoxetine in depressed patients on dialysis. Int. J. Psychiatry Med. 1997, 27(1):71-80.
42. Levy N.B., et al. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. Gen. Hosp. Psychiatry 1996, 18(1):8-13.
43. Atalay H., et al. Sertraline treatment is associated with an improvement in depression and health-related quality of life in chronic peritoneal dialysis patients. Int. Urol. Nephrol. 2010, 42(2):527-536.
44. Kalender B., et al. Antidepressant treatment increases quality of life in patients with chronic renal failure. Ren. Fail. 2007, 29(7):817-822.
45. Kamo T., et al. Efficacy and pharmacokinetics of fluvoxamine maleate in patients with mild depression undergoing hemodialysis. Psychiatry Clin. Neurosci. 2004, 58(2):133-137.
46. Kennedy S.H., Craven J.L., Rodin G.M. Major depression in renal dialysis patients: an open trial of antidepressant therapy. J. Clin. Psychiatry 1989, 50(2):60-63.
47. Koo J.R., et al. Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients. Am. J. Med. Sci. 2005, 329(1):1-5.
48. Turk S., et al. Treatment with antidepressive drugs improved quality of life in chronic hemodialysis patients. Clin. Nephrol. 2006, 65(2):113-118.
49. Wuerth D., et al. Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. Am. J. Kidney Dis. 2001, 37(5):1011-1017.
50. Hosseini S.H., Espahbodi F., Mirzadeh Goudarzi S.M. Citalopram versus psychological training for depression and anxiety symptoms in hemodialysis patients. Iran. J. Kidney Dis. 2012, 6(6):446-451.
51. Cukor D., et al. Psychosocial intervention improves depression, quality of life, and fluid adherence in hemodialysis. J. Am. Soc. Nephrol. 2014, 25(1):196-206.
52. Duarte P.S., et al. Cognitive-behavioral group therapy is an effective treatment for major depression in hemodialysis patients. Kidney Int. 2009, 76(4):414-421.
53. "Clinical Trials Identifier Number NCT02358343. Clinical Trials. Accessed on August 3, 2015.". http://www.clinicaltrials.gov/.
54. Sheehan D.V., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl 20):22-33. (quiz 34-57).
55. Craven J.L., Rodin G.M., Littlefield C. The Beck Depression Inventory as a screening device for major depression in renal dialysis patients. Int. J. Psychiatry Med. 1988, 18(4):365-374.
56. Loosman W.L., et al. Validity of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory for use in end-stage renal disease patients. Br. J. Clin. Psychol. 2010, 49(Pt 4):507-516.
57. Watnick S., et al. The prevalence and treatment of depression among patients starting dialysis. Am. J. Kidney Dis. 2003, 41(1):105-110.
58. Rush A.J., et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 2003, 54(5):573-583.
59. Trivedi M.H., et al. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 2006, 354(12):1243-1252.
60. Ilardi S.S., Craighead W.E. The role of nonspecific factors in cognitive-behavior therapy for depression. Clin. Psychol. Sci. Pract. 1994, 1(2):138-156.
61. Grote N.K., et al. Engaging women who are depressed and economically disadvantaged in mental health treatment. Soc. Work 2007, 52(4):295-308.
62. Melville J.L., et al. Improving care for depression in obstetrics and gynecology: a randomized controlled trial. Obstet. Gynecol. 2014, 123(6):1237-1246.
63. Grote N.K., et al. Culturally relevant treatment services for perinatal depression in socio-economically disadvantaged women: the design of the MOMCare study. Contemp. Clin. Trials 2014, 39(1):34-49.
64. Richardson L.P., et al. Collaborative care for adolescents with depression in primary care: a randomized clinical trial. JAMA 2014, 312(8):809-816.
65. Jain N., et al. Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). Contemp. Clin. Trials 2013, 34(1):136-144.
66. Harding K.J., et al. Measurement-based care in psychiatric practice: a policy framework for implementation. J. Clin. Psychiatry 2011, 72(8):1136-1143.
67. Butler A.C., et al. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin. Psychol. Rev. 2006, 26(1):17-31.
68. Hollon S.D., Ponniah K. A review of empirically supported psychological therapies for mood disorders in adults. Depress. Anxiety 2010, 27(10):891-932.
69. Beck J. Cognitive Therapy: Basics and Beyond 1995, Guilford, New York.
70. Association A.P. Practice Guideline for the Treatment of Patients With Major Depressive Disorder 2010.
71. Beck A. Depression: Causes and Treatment 2006, University of Pennsylvania Press, Philadelphia.
72. Rayner L., et al. Antidepressants for depression in physically ill people. Cochrane Database Syst. Rev. 2010, (3):Cd007503.
73. Lee S.K., et al. The effects of antidepressant treatment on serum cytokines and nutritional status in hemodialysis patients. J. Korean Med. Sci. 2004, 19(3):384-389.
74. Brown E.S., et al. A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study. Biol. Psychiatry 2005, 58(11):865-870.
75. O'Connor C.M., et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J. Am. Coll. Cardiol. 2010, 56(9):692-699.
76. Wisniewski S.R., et al. Self-rated global measure of the frequency, intensity, and burden of side effects. J. Psychiatr. Pract. 2006, 12(2):71-79.
77. University of Pittsburgh Epidemiology Data Center: Inventory of Depressive Symptomatology (IDS) and Quick Inventory of Depressive Symptomatology (QIDS) http://www.ids-qids.org/index.html.
78. Hedayati S.S., et al. Validation of depression screening scales in patients with CKD. Am. J. Kidney Dis. 2009, 54(3):433-439.
79. Hedayati S.S., Yalamanchili V., Finkelstein F.O. A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. Kidney Int. 2012, 81(3):247-255.
80. Jhamb M., et al. Design and rationale of health-related quality of life and patient-reported outcomes assessment in the Frequent Hemodialysis Network trials. Blood Purif. 2011, 31(1-3):151-158.
81. Unruh M., et al. Bias in assessment of health-related quality of life in a hemodialysis population: a comparison of self-administered and interviewer-administered surveys in the HEMO study. J. Am. Soc. Nephrol. 2003, 14(8):2132-2141.
82. Verbeke G., Molenberghs A. Linear Mixed Models for Longitudinal Data 2000, Springer, New York.
83. Littell R.C., Pendergast J., Natarajan R. Modelling covariance structure in the analysis of repeated measures data. Stat. Med. 2000, 19(13):1793-1819.
84. Siegel J. Innovative Methods in Stakeholder Engagement: An Environmental Scan 2012.
85. Schafer J.L. Multiple imputation: a primer. Stat. Methods Med. Res. 1999, 8(1):3-15.
86. Federal Register Regulation, 405.2163 1976.
87. Borson S., et al. The mini-cog: a cognitive 'vital signs' measure for dementia screening in multi-lingual elderly. Int. J. Geriatr. Psychiatry 2000, 15(11):1021-1027.